Satellos Bioscience Inc. (MSLE)

Satellos Bioscience Inc. (MSLE) is a clinical-stage biotechnology company based in Toronto, Canada, focused on restoring the body's ability to regenerate damaged skeletal muscle.

Its research centers on muscle stem cell polarity and the signaling that controls how stem cells divide to repair muscle. Using its proprietary discovery platform, the company develops small-molecule drugs intended to correct defects in this regenerative process. Its lead candidate, SAT-3247, is an oral drug being developed for Duchenne muscular dystrophy, with the aim of improving muscle function regardless of the specific genetic mutation a patient carries. The company is also exploring applications in other degenerative and injury-related muscle conditions.